CN107625767A - A kind of medicine for treating chronic pelvic inflammatory disease - Google Patents
A kind of medicine for treating chronic pelvic inflammatory disease Download PDFInfo
- Publication number
- CN107625767A CN107625767A CN201710973021.5A CN201710973021A CN107625767A CN 107625767 A CN107625767 A CN 107625767A CN 201710973021 A CN201710973021 A CN 201710973021A CN 107625767 A CN107625767 A CN 107625767A
- Authority
- CN
- China
- Prior art keywords
- medicine
- inflammatory disease
- agent
- compound
- chronic pelvic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
Abstract
The present invention relates to a kind of medicine for treating chronic pelvic inflammatory disease, the medicine includes the compound and pharmaceutically acceptable carrier with structural formula described herein of effective dose, wherein R1 independently selected from：F, Cl, Br or I；R2 independently selected from：H, the alkyl of C1 6 optionally substituted by halogen, hydroxyl, alkoxy, alkoxy carbonyl, amino；R3 independently selected from：H, the alkyl of C1 6 optionally substituted by halogen, hydroxyl, alkoxy, alkoxy carbonyl, amino.The degree of inflammation in uterus caused by the medicine of the present invention can mitigate chronic pelvic inflammatory disease.
Description
Technical field
The present invention relates to field of medicaments, and specifically, the present invention relates to a kind of medicine for treating chronic pelvic inflammatory disease.
Background technology
Chronic pelvic inflammatory disease refers to female internal genital organs and its surrounding connective tissue, the chronic inflammation of pelvic peritoneum.Its is main
Clinical manifestation is paramenia, leucorrhea increasing, waist abdomen pain and infertile etc., has such as formed chronic appendages inflammation, then accessible lump.
Symptom is visible：1) chronic pelvic pain：The cicatricial adhesion and pelvic congestion that chronic inflammation is formed, often cause lower abdomen falling inflation, pain
Pain and lumbosacral region are ached.Often aggravate after tired, sexual intercourse and before and after menstruation.2) infertile and ectopic pregnancy：Fallopian tube adhesion blocks
Infertile and ectopic pregnancy can be caused.Infertile incidence is 20%~30% after acute pelvitis of pelvic cavity.3) menoxenia：Endometritis is normal
There is irregular menses；Pelvic congestion can cause menorrhagia；Ovarian function can cause menstrual disorder when damaging.4) constitutional symptom：More not
Substantially, only low-heat sometimes, it is susceptible tired.Because course of disease time is longer, some patientss may occur in which neurasthenia symptom, such as spirit
Depressed, whole body discomfort, insomnia etc..When patient's resistance difference, acute or subacute breaking-out is tended to have.Sign, if endometrium
Inflammation, uterus increase, tenderness；If salpingitis, then the thickening fallopian tubal in rope strip is contacted in uterus one or both sides, and have
Mild tenderness.If hydrosalpinx or tubo-ovarian cyst, then Cystic lesions are touched in pelvic cavity one or both sides, activity is more
It is limited.During if connective tissue inflammation of pelvic cavity, uterus is in often retroversioflexion, and limitation of activity or adhesion are fixed, uterus one or both sides
There is sheet to thicken, tenderness, the normal thickening of uterosacral ligament, be hardened, there is tenderness.Chronic pelvic inflammatory disease is common gynecological disease.In China,
Due to the limitation of personal hygiene condition and medical condition, or the sterile working idea in gynaecology's minor operation and family planning operation
Indifferent, the incidence of disease of chronic pelvic inflammatory disease is very high.
The content of the invention
It is an object of the invention to provide a kind of medicine for treating chronic pelvic inflammatory disease.
In order to realize the purpose of the present invention, the present invention provides a kind of medicine for treating chronic pelvic inflammatory disease, and the medicine includes
Effective dose has following structural compound and pharmaceutically acceptable carrier：
, wherein
R1 independently selected from：F, Cl, Br or I；
R2 independently selected from：H, the C optionally substituted by halogen, hydroxyl, alkoxy, alkoxy carbonyl, amino1-6Alkyl；
R3 independently selected from：H, the C optionally substituted by halogen, hydroxyl, alkoxy, alkoxy carbonyl, amino1-6Alkyl.
Preferably, R1 Br.
Preferably, R2 H.
Preferably, R3 H.
The present invention also provides a kind of method for treating chronic pelvic inflammatory disease, and methods described is included to the object for needing this kind for the treatment of
Give the medicine or its pharmaceutically acceptable salt any one of the claim 1-4 of effective dose.
The present invention also provides purposes of the compound with following structural in the medicine for preparing treatment chronic pelvic inflammatory disease：
, wherein
R1 independently selected from：F, Cl, Br or I；
R2 independently selected from：H, the C optionally substituted by halogen, hydroxyl, alkoxy, alkoxy carbonyl, amino1-6Alkyl；
R3 independently selected from：H, the C optionally substituted by halogen, hydroxyl, alkoxy, alkoxy carbonyl, amino1-6Alkyl.
Preferably, R1 Br.
Preferably, R2 H.
Preferably, R3 H.
Before further describing the invention, it should be appreciated that the invention is not restricted to described embodiment, because they
Certainly may change.It should also be understood that the purpose of terms used herein is only description embodiment, it is not used to be construed as limiting,
Because the scope of the present invention is only limited by the appended claims.
Unless otherwise indicated, all scientific and technical terminologies used herein are understood with one skilled in the art of the present invention
Usual implication it is identical.All reference is incorporated into full for all patents referred to herein, application, published application and other publications
Herein.If it is opposite that definition listed in this paper patent, application and other publications is included in definition in the part with reference
Or it is inconsistent, the definition in the part, which will overwhelm, quotes the definition for including this paper.
Herein and the singulative used in appended claims "one", " one kind " and " described " include plural indicate
Thing, unless the context.It should also be noted that claims can be formulated as excluding any optional key element.Equally,
This explanation application makees reference claim element and relatively uses this kind of removing property term, such as " only having ", " only ", or make
With the antecedent basis of " negative " limitation.
Terms used herein "comprising", " containing " and " comprising " are used with its opening, infinite implication.
To provide conciser description, without using term " about " before some quantitative expressions herein.It should be understood that either
No clearly to use term " about ", each content herein represents the numerical value actually given, and it is also represented by being based on ability
The approximation for the given numerical value that domain ordinary skill can rationally infer, including due to this kind of caused by experiment and/or measuring condition
The equivalent value and approximation of given numerical value.No matter when as a percentage during yield, this kind of yield is represented in specific chemistry
Measure and can be obtained the maximum amount of ratio with same entity for calculating the entity quality of yield than under the conditions of.Percents
Concentration represent quality ratio, unless otherwise indicated.
Unless otherwise indicated, all scientific and technical terminologies used herein are understood with one skilled in the art of the present invention
Usual implication it is identical.Although it can also use and implement or test this hair with similar or equivalent any method described herein and material
It is bright, but preferable method and material are described below.All publications being mentioned above are totally incorporated herein by reference, and cited
Publication, which is associated, comes these methods of disclosure and description and/or material.
Unless otherwise indicated, the methods and techniques of embodiment of the present invention typically follow conventional method well known in the art and entered
Described in the bibliography of row simultaneously such as some in generals or particularly, the bibliography is quoted and discussed through this specification.
See, e.g., Loudon, OrganicChemistry (《Organic chemistry》), fourth edition；New York：Oxford University Press
(OxfordUniversityPress), 2002,360-361,1084-1085 page；Smith and March, March '
sAdvancedOrganicChemistry：Reactions, Mechanisms, andStructure (《Numb chi is advanced to organise
Learn：Reaction, mechanism and structure》), the 5th edition, Wei Li scientific companies (Wiley-Interscience), 2001.
It is used to name the nomenclature of motif compound in the embodiments herein to illustrate herein.The nomenclature typically uses city
Available AutoNom softwares (the MDL companies of Andrew in the sage of California) are sold, version 12.0.2 is obtained.
It should be understood that for clarity, some features of the invention described in the content of single each embodiment are also
It may be incorporated in single embodiment and provide.Conversely, in the content of single embodiment Short Description it is of the invention
Each feature can also be provided separately or be provided in the form of any suitable sub-portfolio.With the chemical base represented by changeable-shaped
All combinations of the related embodiment of group are specific to be included in the scope of the invention and by being disclosed herein, just as herein individually and
Compound (that is, separable, table of each and each combination down to such combination comprising itself for stable compound is clearly disclosed
The compound for detection biological activity of seeking peace).In addition, chemical group listed in describing the embodiment of such changeable-shaped
All sub-portfolios are also specifically included in the scope of the invention and by being disclosed herein, just as disclosing individually and clearly chemical base herein
Each and each such sub-portfolio of group.
" pharmaceutically acceptable salt " is intended to indicate that the free acid of compound illustrated herein or the salt of alkali, its do not have toxicity,
It can biologically tolerate or biologically be suitable to be administered to object.Generally referring to, S.M.Berge etc.,
“PharmaceuticalSalts(《Pharmaceutical salts》) " J.Pharm.Sci., 1977,66,1-19.It is preferable pharmaceutically acceptable
Salt be pharmaceutically effectively and be adapted for contact with object tissue without excessive toxicity, stimulate or it is anaphylactoid those.Herein
Described compound can have group acid enough, the enough group of alkalescence, two kinds of functional group or each more than a kind of
Type, and therefore with a variety of inorganic or organic base, and inorganic and organic acid reaction to form pharmaceutically acceptable salt.
The example of pharmaceutically acceptable salt includes sulfate, pyrosulfate, disulfate, sulphite, bisulfite
Salt, phosphate, dibasic alkaliine, dihydric phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetic acid
Salt, propionate, caprate, caprylate, acrylates, formates, isobutyrate, caproate, enanthate, propiolate, oxalic acid
Salt, malonate, succinate, suberate, sebacate, fumarate, maleate, Isosorbide-5-Nitrae-acetylenedicarboxylic acid salt, 1,6-
Hexyndioic acid salt, benzoate, chloro benzoate, methyl benzoic acid salt, dinitro-benzoate, hydroxy benzoate, methoxy
Yl benzoic acid salt, phthalate, sulfonate, metilsulfate, propyl sulfonic acid salt, benzene sulfonate, xylenesulfonate,
Naphthalene -1- sulfonate, naphthalene-2-sulfonic acid salt, phenyl acetate salt, phenylpropionic acid salt, PB, citrate, lactate, γ -
Hydroxybutyric acid salt, glycollate, tartrate and mandelate.The list of other suitable pharmaceutically acceptable salts is found in
Remington′sPharmaceuticalSciences(《Remington pharmaceutical science》), the 17th edition, Easton, PA
Mack Publishing Company (MackPublishingCompany), 1985.
It may also include and one or more can pharmaceutically connect for the pharmaceutical composition of therapeutic purposes, including compound described herein
The excipient received.Pharmaceutically acceptable excipient refers to no toxicity and is biologically suitable to the material being administered to object.It is this kind of
Excipient promotes the administration process of compound described herein and compatible with active component.The example of pharmaceutically acceptable excipient
Including stabilizer, lubricant, surfactant, diluent, antioxidant, binding agent, colouring agent, swelling agent, emulsifying agent or tune
Taste agent.In a preferred embodiment, the pharmaceutical composition of the invention is aseptic composite.It can be used known to those skilled in the art
Or the complex technique that can be used prepares pharmaceutical composition.
The present invention also relates to aseptic composite, including meet the country for determining said composition and the composition of local code.
The conventional method prepared according to a variety of formulations are used in this area, pharmaceutical composition and compound described herein can match somebody with somebody
Solution, emulsion, supensoid agent or the dispersant being made as in appropriate drug solvent or supporting agent, or pill, tablet, lozenge, suppository,
Wafer, sugar-coat agent, granule, powder agent, the powder agent for reconstruction or the capsule together with solid carriers.The medicine of the present invention
Composition can be given by appropriate route of delivery, such as oral, parenteral, rectum, intranasal, part or through eye approach, or lead to
Cross suction.Preferably, said composition is formulated as being used for administered intravenously or orally.
For being administered orally, compound of the invention can (such as tablet or capsule) or solution, emulsion in solid form
Or the form of supensoid agent provides.To prepare Orally administered composition, compound of the invention can be prepared to form such as daily about 0.01
To about 50mg/kg or daily about 0.05 to about 20mg/kg or daily about 0.1 to about 10mg/kg dosage.Other dosage include
Daily about 0.1mg to 1g, daily about 1mg to about 10mg, daily about 10mg to about 50mg, daily about 50mg to about 250mg or every
Its about 250mg to 1g.Oral tablet may include and compatible pharmaceutically acceptable excipient (such as diluent, disintegrant, bonding
Agent, lubricant, sweetener, flavor enhancement, colouring agent and preservative) mixing active component.Suitable inert filler includes carbonic acid
Sodium and calcium carbonate, sodium phosphate and calcium phosphate, lactose, starch, sugar, glucose, methylcellulose, magnesium stearate, mannitol, sorb
Sugar alcohol etc..Exemplary fluids oral vehicle includes ethanol, glycerine, water etc..Starch, polyvinylpyrrolidone (PVP), starch second
Alkyd sodium, microcrystalline cellulose and alginic acid are exemplary disintegrants.Bonding agent may include starch and gelatin.If it does, lubrication
Agent can be magnesium stearate, stearic acid or talcum.If desired, certain material (such as glycerin monostearate or two can be used
Tristerin) coating tablet is with the absorption in delaying stomach and intestine road, or uses enteric coating peridium.
Capsule for oral administration includes hard and Perle.To prepare hard gelatin capsule, can by active component with
Solid, semisolid or liquid diluent mixing.Perle can be by by active component and water, oil (such as peanut oil or olive
Olive oil), atoleine, the mixture of the list of short chain fatty acids and two glyceride, the mode of polyethylene glycol 400 or mixed with propylene glycol
Prepare.
Liquid for oral administration can be the form of supensoid agent, solution, emulsion or syrup, or can face
The dry products rebuild with preceding water or other suitable supporting agents.This kind of fluid composition is optional to be included：Pharmaceutically acceptable tax
Shape agent, as suspending agent (such as D-sorbite, methylcellulose, mosanom, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose,
Aluminium stearate gel etc.)；Non-aqueous supporting agent, such as oily (such as apricot kernel oil or fractionated coconut oil), propane diols, ethanol or water；It is anti-
Rotten agent (such as methyl p-hydroxybenzoate or propylparaben or sorbic acid)；Wetting agent (such as lecithin)；And (such as
Fruit needs) flavor enhancement or colouring agent.
The composition of the present invention can be formulated as suppository and be used for rectally.(including intravenous, muscle is used for parenteral
Interior, intraperitoneal, intranasal or subcutaneous route), reagent of the invention can be buffered to suitable pH with aseptic aqueous solution agent or supensoid agent
With isotonicity or by it is parenteral it is acceptable it is oily in the form of provide.Suitable aqueous carrier includes Ringer's solution and isotonic
Sodium chloride.This kind of form can be that unit dosage form (such as ampoule or disposable injection device), multiple dose form (such as can be from
The middle medicine bottle for taking out suitable dose) or solid form or available for the pre-concentration liquid for preparing injectable formulation.At several minutes to number
In it time, the scope of exemplary infusion dosage is the reagent mixed with drug-carrier of about 1 to 1000 μ g/kg/ minutes.
For intranasal, suction or oral administration, the spray agent for for example also including suitable carrier can be used to give this hair
Bright pharmaceutical composition.
For local use, the compound of the present invention is preferably formulated as emulsifiable paste or ointment or the class suitable for being locally administered
Like supporting agent.For local administration, the compound of the present invention can be mixed with drug-carrier, concentration is the pact that medicine accounts for supporting agent
0.1% to about 10%.Another pattern for giving the reagent of the present invention is to reach the effect of transdermal delivery using patch formulation.
Terms used herein " treatment " or " processing " include " preventative " and " therapeutic " treatment." preventative " treatment, which refers to, to be pushed away
The symptom or reduce disease or symptom development or recurrence that slow disease, the development of disease symptomses or medical conditions, suppression are likely to occur
Risk." therapeutic " treatment includes reducing existing disease, the order of severity of symptom or illness or suppresses its deterioration.Therefore, control
Treat the deterioration for including improving or preventing existing disease symptomses, the essence system for preventing other symptoms, improving or preventing symptom
System reason, suppress imbalance or disease, such as prevent imbalance or advancing of disease, mitigation imbalance or disease, promote imbalance or disease
Regression, mitigate illness caused by disease or imbalance or stop disease or the symptom of imbalance.
Term " object " refers to the mammalian subject for needing the treatment, such as people.
In the treatment method according to the present invention, " effective dose " refers to be controlled needed for the object acquisition for being enough to make this kind for the treatment of of needs
Treat the amount or dosage of benefit.The present invention compound effective dose or dosage can by conventional method (as modeling, dosage escalation or
Clinical test) determine, wherein consider conventional factors, such as the pattern or approach of administration or medicine delivery, the medicine of reagent are for power
The judgement of the order of severity and process, the health status of object, the state of an illness and body weight and the doctor in charge that learn, infect.Exemplary dose
The scope of amount is daily per Kilogram subject body weight about 1ug to 2mg active agent, preferably from about 0.05 to 100mg/kg/ days or about 1
To 35mg/kg/ days or about 0.1 to 10mg/kg/ days.In other embodiments, the scope of exemplary dose is about 1mg to about
1g/ days, or about 1-500,1-250,1-100,1-50,50-500 or 250-500mg/ days.Accumulated dose can be with single or separated
Dosage device (such as BID, TID, QID) is given.
Once the disease of patient improves, you can regulating dosage is used for preventative or maintaining treatment.For example, the agent of administration
Amount or frequency or both can change to be down to symptom keeps the required level for treating or preventing effect.Certainly, if symptom
Mitigate to proper level, can stop treating.But during any symptom recurrence, patient can require that the interval in long-term basis is controlled
Treat.Patient may also need to the long-term treatment on the basis of long time-histories.
Retouched by reference to specific embodiment with the schematic synthetic schemes of general preparative methods in this article and afterwards
State Exemplary chemical entity useful in the method for the present invention.Those skilled in the art will appreciate that to obtain herein more
Kind compound, can suitably be selected parent material, so as to which the reaction scheme protected by suitably with or without makes
With final required substituent to generate required product.Or, it may be necessary to or want in final required substituting group position
Upper use can pass through the proper group that reaction scheme is carried and can substituted in due course by required substituent.In addition, this area skill
The order that art personnel should be understood that the conversion shown in following scheme and arbitrarily can hold with specific side base function phase is carried out.It is general
Each reaction described in scheme is preferably carried out under about 0 DEG C to the reflux temperature of organic solvent used.All material generally may be used
Bought at market supply business.
The degree of inflammation in uterus caused by the medicine of the present invention can mitigate chronic pelvic inflammatory disease.
Brief description of the drawings
Fig. 1 is that phenol paste causes rat chronic pelvic infecton model pathological section (× 100), wherein A：Normal group；B：
Model control group；C：Positive controls；D、E、F：The high, medium and low dosage group of medicine of the present invention.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not the limit to the present invention
System, those skilled in the art according to the present invention basic thought, various modifications may be made or improve, but without departing from this
The basic thought of invention, within the scope of the present invention.
Experimental example
The structural formula of medical compounds of the present invention is：
Take female sd inbred rats, 190~230g of weight.Rat is anaesthetized through yellow Jackets (30mg/kg, i.p.), back of the body position is consolidated
Due on operating table, after belly routine disinfection, median incision of lower abdomen about 2cm exposes uterus, with No. 4 syringe needles respectively in uterus bifurcated
Locate careful inserting needle, compound each 0.075mL of phenol paste is slowly injected into ovary direction, note is finished, and abdomen, sterilization art area are closed in layering.Make
Mould terminates.
If Normal group, model control group, positive controls (JINJI KELI, purchased from the limited public affairs of Hang Seng of Zhongshan city medicine company
Department) and the high, medium and low dosage group of medicine of the present invention, every group 10, wherein Normal group does not carry out modeling.It is grouped within postoperative 2nd day
Administration, positive controls dosage is daily 12.5g raw medicinal herbs/kg, is made into suspension oral gavage with distilled water before use, continuously
Gavage 14d.0.01g the compounds of this invention is taken to add 2000mL normal salines into suspension, high, normal, basic dose of medicine of the present invention
Amount group distinguishes daily gavage 10mL/100g, 5mL/100g, 2.5mL/100g, continuous gavage 14d.Normal group and model pair
Distilled water, administered volume 2mL/100g, continuous gavage 14d are given according to a group gavage.Animal is put to death within 15th day, rat is taken out in separation
Uterus, after weighing, 10% formalin is put into uterus and fixed, made paraffin section, HE dyeing, make histology microscopy.
Standards of grading
Cavity wall structure：Each clear layer is "-"；Proper mucous membrane gland structure is disorderly unclear or disappearance is "+"；Muscle layer and mucous membrane
Unclear stratum boundary limit is " ++ "；Unclear holostrome structure is " +++ ".
Epithelial cell：Simple columnar is "-"；Cell is flat or downright bad come off less than 1/3 of epithelial cell is "+"；More than 1/3
For " ++ "；It is " +++ " that necrosis, which disappears, completely.
Inner membrance congestion and edema：It is "-" without congestion and edema；The slight congestion and edema of lamina propria is "+"；Obvious congestion and edema for "+
+”；It is " +++ " that muscle layer or even placenta percreta, which have congestion and edema,.
Chronic cell infiltration：Lymphocyte, thick liquid cell in 10 × 20 times of lower 4 unit areas of number of micrometer grid
Number, takes its average.Each layer has no that inflammatory cell is "-"；It is "+" only to be seen a large amount of in proper mucous membrane；Also visible, the quantity in muscle layer
20~30 are " ++ "；Holostrome all has, quantity be more than 30 for " +++
Fibroblast：It is "-" without hyperplasia；It is "+" that proper mucous membrane, which has a small amount of,；Muscle layer also has, and amount is relatively mostly " ++ "；Holostrome is all
Have, quantity is " +++ " more than 30.
Uterine cavity size：Uterine cavity reduces or degrees of expansion person within 1/3 is slight lesion, and more than 1/3 to 2/3 is moderate
Lesion, it is moderate lesion more than 2/3.
Every kind of lesion degree from light to heavy labeled as+, ++, +++, ++++, no lesion person be "-", respectively scoring be 1 point, 2
Divide, 3 points, 4 points, 0 point.Add up all fractions, calculates dividing equally for every group of animal, the higher prompting inflammation disease of score value
Change degree is more serious.
Statistical procedures
Statistical analysis is carried out with SPSS17.0 softwares.Data are with mean ± standard deviationRepresent, more group differences are adopted
With variance analysis, two groups of group differences are examined with Dunnett-t.P<0.05 represents that difference is statistically significant.
Pathology results
See Fig. 1.Phenol paste causes rat chronic pelvic infecton model result to show：Model group metrosynizesis, diminish, a small number of cases
Uterine cavity is expanded, endometrium lamina propria fibroblast proliferation, and produces collagenic connective tissue, causes palace wall proliferation of fibrous tissue,
Obvious person's part palace wall normal configuration disappears, and is that the fiber of collagenzation substitutes.Positive drug and medicine of the present invention can mitigate chronic basin
The degree of inflammation in uterus caused by chamber inflammation, show as endometrial epithelium denaturation, muscle layer congestion and edema and cell infiltration and consolidate
There are layer, basic unit's inflammatory reaction to mitigate.
Medicine Pyrogentisinic Acid paste of the present invention causes the influence of rat uterus inflammation change degree see the table below.
Compare with Normal group, * P<0.05, represent modeling success；Compare with model control group,ΔP<0.05, represent effect
Fruit has significant difference；Compare with positive controls,&P<0.05, represent that effect has significant difference.
Claims (1)
1. the compound with following structural prepare endometrial epithelium denaturation, muscle layer congestion and edema and cell infiltration with
And the purposes in the medicine that mitigates of lamina propria, basic unit inflammatory reaction：
, the compound and one or more are pharmaceutically acceptable
Excipient form pharmaceutical composition, the composition be formulated as be used for administered intravenously or orally.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710973021.5A CN107625767A (en) | 2016-11-25 | 2016-11-25 | A kind of medicine for treating chronic pelvic inflammatory disease |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611055679.XA CN106474121B (en) | 2016-11-25 | 2016-11-25 | A kind of medicine for treating chronic pelvic inflammatory disease |
| CN201710973021.5A CN107625767A (en) | 2016-11-25 | 2016-11-25 | A kind of medicine for treating chronic pelvic inflammatory disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611055679.XA Division CN106474121B (en) | 2016-11-25 | 2016-11-25 | A kind of medicine for treating chronic pelvic inflammatory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107625767A true CN107625767A (en) | 2018-01-26 |
Family
ID=58275463
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710973021.5A Withdrawn CN107625767A (en) | 2016-11-25 | 2016-11-25 | A kind of medicine for treating chronic pelvic inflammatory disease |
| CN201611055679.XA Active CN106474121B (en) | 2016-11-25 | 2016-11-25 | A kind of medicine for treating chronic pelvic inflammatory disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611055679.XA Active CN106474121B (en) | 2016-11-25 | 2016-11-25 | A kind of medicine for treating chronic pelvic inflammatory disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN107625767A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106132960A (en) * | 2014-01-29 | 2016-11-16 | 神经孔疗法股份有限公司 | Heteroaryl amide as protein aggregation inhibitor |
-
2016
- 2016-11-25 CN CN201710973021.5A patent/CN107625767A/en not_active Withdrawn
- 2016-11-25 CN CN201611055679.XA patent/CN106474121B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106132960A (en) * | 2014-01-29 | 2016-11-16 | 神经孔疗法股份有限公司 | Heteroaryl amide as protein aggregation inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106474121A (en) | 2017-03-08 |
| CN106474121B (en) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6920379B2 (en) | Reduction of adipose tissue | |
| Laube | Skin infections and ageing | |
| Yamamoto et al. | Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C | |
| CN101848711A (en) | A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases | |
| Bellina | The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up | |
| HUE025239T2 (en) | Methods for the treatment of endometriosis | |
| Sarkar et al. | Comparison of preoperative nepafenac (0.1%) and flurbiprofen (0.03%) eye drops in maintaining mydriasis during small incision cataract surgery in patients with senile cataract: A randomized, double-blind study | |
| Schurmans et al. | Macular hole surgery with inner limiting membrane peeling, endodrainage, and heavy silicone oil tamponade | |
| Liu et al. | Modified lamellar keratoplasty and immunosuppressive therapy guided by in vivo confocal microscopy for perforated Mooren's ulcer | |
| CN106474121B (en) | A kind of medicine for treating chronic pelvic inflammatory disease | |
| Sokal et al. | Transcervical quinacrine sterilization: clinical experience | |
| Fernandez-Garcia et al. | Corneal thickness differences between sexes after oxybuprocaine eye drops | |
| CN106580982B (en) | A kind of medicine of medicine post-abortion metrorrhagia | |
| Xin et al. | Establishing a mouse model of choroidal neovascularization to study the therapeutic effect of levotinib and its mechanism | |
| COHEN et al. | Essential shrinkage of conjunctiva in a case of probable epidermolysis bullosa dystrophica | |
| Frankel | Field guide to clinical dermatology | |
| Edwards et al. | The side-effects of antipsychotic drugs. II. Effects on other physiological systems | |
| CN106551938B (en) | A kind of medicine for treating NASH and its application | |
| TUCKER | Cause and treatment of pruritus ani | |
| Kumar et al. | The Genital, Perianal, and Umbilical Regions | |
| Rubinstein et al. | Microarchitecture of schlemm canal before and after cataract extraction surgery | |
| Kumari et al. | Clinical Evaluation Of Efficacy Of Kusthadi Churna With Udumbaradi Tail In The Management Of Karnini Yonivyapada WSR To Cervical Erosion | |
| Lee et al. | Effects of the peptide leukotriene receptor antagonist ICI 198,615 on the in vivo and in vitro changes in guinea pig bladder function which occur after sensitization with ovalbumin | |
| Gazzard et al. | Selective laser trabeculoplasty: physiology and effects of SLT | |
| Cuscheri et al. | Disorders of Skin and Soft Tissues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180126 |
|
| WW01 | Invention patent application withdrawn after publication |